Insider Selling: Spyre Therapeutics (NASDAQ:SYRE) CFO Sells $688,725.00 in Stock

Key Points

• Spyre Therapeutics CFO Scott Burrows sold 7,500 shares for approximately $688,725 at an average price of $91.83 under a pre-arranged Rule 10b5-1 plan, reducing his holdings by 8.59%.
• SYRE shares rose 3.6% to $93.19, while the company reported a quarterly loss of $0.36 per share—better than the consensus estimate of a $0.76 loss.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and an average price target of $109.71; institutional investors own 80.39% of the stock.

Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CFO Scott Burrows sold 7,500 shares of the stock in a transaction that occurred on Thursday, October 1st. The shares were sold at an average price of $91.83, for a total transaction of $688,725.00. Following the completion of the sale, the chief financial officer directly owned 79,762 shares of the company's stock, valued at $7,324,544.46. This trade represents a 8.59% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Spyre Therapeutics Stock Up 3.6%

Shares of NASDAQ SYRE traded up $3.26 during trading on Friday, reaching $93.19. 1,235,015 shares of the stock were exchanged, compared to its average volume of 1,229,962. Spyre Therapeutics, Inc. has a twelve month low of $15.86 and a twelve month high of $110.18. The company has a market capitalization of $8.20 billion, a price-to-earnings ratio of -47.79 and a beta of 3.10. The business's 50-day moving average price is $95.71 and its 200 day moving average price is $81.43.

Spyre Therapeutics (NASDAQ:SYRE - Get Free Report) last announced its earnings results on Tuesday, August 4th. The company reported ($0.36) earnings per share for the quarter, beating the consensus estimate of ($0.76) by $0.40. As a group, sell-side analysts expect that Spyre Therapeutics, Inc. will post -2.71 earnings per share for the current fiscal year.

Analysts Set New Price Targets

SYRE has been the subject of several research analyst reports. Wedbush reiterated an "outperform" rating and set a $123.00 target price on shares of Spyre Therapeutics in a research note on Wednesday, September 9th. BTIG Research reaffirmed a "buy" rating and issued a $121.00 price target on shares of Spyre Therapeutics in a report on Thursday. Deutsche Bank Aktiengesellschaft reduced their price objective on shares of Spyre Therapeutics from $135.00 to $127.00 and set a "buy" rating on the stock in a research note on Wednesday, August 26th. Robert W. Baird set a $120.00 target price on shares of Spyre Therapeutics in a research report on Wednesday, August 5th. Finally, Wolfe Research cut shares of Spyre Therapeutics from an "outperform" rating to a "peer perform" rating in a research report on Tuesday, July 28th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, Spyre Therapeutics currently has a consensus rating of "Moderate Buy" and a consensus target price of $109.71.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. GAMMA Investing LLC grew its holdings in shares of Spyre Therapeutics by 26.8% during the second quarter. GAMMA Investing LLC now owns 663 shares of the company's stock valued at $59,000 after purchasing an additional 140 shares during the last quarter. Integrated Wealth Concepts LLC bought a new position in Spyre Therapeutics during the 2nd quarter worth $31,000. Summit Securities Group LLC acquired a new stake in Spyre Therapeutics in the first quarter worth $28,000. Royal Bank of Canada lifted its stake in Spyre Therapeutics by 63.5% in the first quarter. Royal Bank of Canada now owns 3,250 shares of the company's stock valued at $164,000 after buying an additional 1,262 shares during the last quarter. Finally, KBC Group NV acquired a new position in shares of Spyre Therapeutics during the first quarter valued at $69,000. 80.39% of the stock is currently owned by institutional investors.

Spyre Therapeutics Company Profile

Spyre Therapeutics, Inc is a clinical-stage biotechnology company focused on developing antibody therapeutics for inflammatory bowel disease (IBD), including ulcerative colitis and Crohn's disease. The company is working to create next-generation biologic medicines intended to address significant treatment needs in these chronic gastrointestinal conditions.

Spyre's pipeline includes programs directed at validated inflammatory pathways, including interleukin-23 (IL-23) and tumor necrosis factor-like ligand 1A (TL1A).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.